Moderna (NASDAQ:MRNA) Now Covered by Berenberg Bank

Berenberg Bank initiated coverage on shares of Moderna (NASDAQ:MRNA) in a research report report published on Tuesday, MarketBeat Ratings reports. The brokerage issued a hold rating and a $42.00 target price on the stock.

A number of other brokerages also recently commented on MRNA. Jefferies Financial Group dropped their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday. Bank of America decreased their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Finally, Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Trading Down 5.6 %

Shares of NASDAQ MRNA opened at $37.29 on Tuesday. The stock has a market capitalization of $14.35 billion, a P/E ratio of -6.41 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The business’s 50 day moving average is $57.82 and its two-hundred day moving average is $96.07. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm posted ($1.39) EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. As a group, research analysts expect that Moderna will post -9.43 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Several large investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new position in Moderna during the second quarter worth approximately $26,000. Family Firm Inc. purchased a new position in shares of Moderna during the second quarter worth $33,000. Bank & Trust Co acquired a new position in Moderna in the 2nd quarter valued at about $36,000. Hanseatic Management Services Inc. acquired a new position in shares of Moderna in the second quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd increased its position in shares of Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after acquiring an additional 288 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.